Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 13/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887209 | 0.91 | HTR6 (0.47) | METHTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3886630 | 0.89 | HTR6 (0.49) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3896698 | 0.88 | HTR6 (0.50) | METHTR6 | |
| SCHEMBL3894879 | 0.87 | HTR6 (0.48) | HTR6HTR2AHTR2CHTR7ALDH1A1 | |
| SCHEMBL3886942 | 0.84 | HTR6 (0.47) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3888250 | 0.84 | HTR6 (0.67) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3890030 | 0.83 | HTR6 (0.69) | METHTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3893909 | 0.83 | HTR6 (0.69) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3889155 | 0.83 | MET (0.49) | METHTR6HTR2AHTR2CHTR7 | |
| SCHEMBL3886893 | 0.83 | HTR6 (0.56) | HTR6HTR2AHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585876-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080114023-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-05-15 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-20050020598-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
| US-6800640-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | MET 1112/4885HTR6 1/4885HTR2A 4/4885 |
| US-20050020598-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR7 | MET 1267/4885HTR6 1/4885HTR2A 4/4885 |
| US-20080114023-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR5A, HTR7 | MET 1267/4885HTR6 1/4885HTR2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.